Developer docs
API playgroundTry for free, no card

Search company profiles

SBX Corporation

Full company profile

uuid000so3k

Namestring
SBX Corporation
Legal namestring
SBX Corporation
Websiteurl
sbx-corp.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

SBX Corporation is a private Tokyo-based AI company founded on April 5, 2011, focused on building infrastructure for AI-driven scientific discovery in biomedicine and drug discovery. Its core technology stack consists of three proprietary platforms: Garuda Platform, which provides an open, community-driven framework for connecting and automating diverse biological data, devices, and analytics; Taxila Platform, an NLP/NLU-based text mining and intelligence engine for context-aware scientific literature analysis; and Gandhara AI Framework, an ensemble-learning system that integrates multiple machine learning and deep learning algorithms to deliver actionable and explainable insights in biomedicine. The company applies these platforms to drug discovery, clinical trials, healthcare, and adjacent domains.

SBX serves enterprise customers primarily through B2B co-development partnerships, joint research, and consulting engagements rather than standardized product sales. Named enterprise customers include POLA Chemical Industries (joint AIM POLAR R&D platform for cosmetics formulation) and Eisai (long-running AI mutagenicity prediction research). Revenue streams derive from R&D collaboration, custom software platform development and maintenance, and consulting services. The company operates through a group structure that includes the parent SBX Corporation (Tokyo), SBX Technologies Corporation (AI/ML, IoT, and model-based simulation), SBX BioSciences, Inc. (Vancouver, Canada, established 2020), and the affiliated non-profit Systems Biology Institute.

The company is led by President Hiroaki Kitano, Ph.D., a recognized pioneer in systems biology, supported by a team of Ph.D.-level scientists and engineers. With 11-50 employees and registered capital of JPY 5,000,000, SBX is a small, research-oriented firm that leverages academic publications, open-standards community participation (Garuda Alliance, SBML, SBGN, OpenTox), and conference engagement as core credibility and demand-generation channels, alongside direct enterprise relationships.

Short descriptiontext

SBX Corporation is a private Tokyo-based AI company that builds proprietary platforms (Garuda, Taxila, Gandhara) for AI-driven scientific discovery in biomedicine and drug discovery, serving enterprise pharmaceutical and cosmetics clients through co-development partnerships and consulting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, biomedical AI platforms, systems biology software, predictive toxicology AI, cosmetics R&D AI
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Computer Systems Design and Related Services54151
  • Custom Computer Programming Services541511
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming Services7371
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Platforms
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1R&D Collaboration and Joint Development
TypeProfessional Services
Description

SBX engages in co-development partnerships with pharmaceutical and cosmetics companies, building custom AI platforms and solutions. Revenue derived from collaborative development projects, such as the AIM POLAR platform with POLA Chemical Industries and mutagenicity prediction systems with Eisai.

sbx-corp.com
2Software Platform Development and Customization
TypeLicensing Royalties
Description

Development, customization and maintenance of software platforms for drug discovery and life science research. Provides platforms (Garuda, Taxila, Gandhara) that can be customized for specific client needs.

sbx-corp.com
3Consulting Services
TypeProfessional Services
Description

Information provision and consulting on life science, drug discovery, and medical fields. R&D consulting and joint development services in drug discovery and personal genome areas.

sbx-corp.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Garuda Platform
Description

Open, community-driven platform providing framework to connect, discover and navigate through different applications, databases and services in biology and medicine. Also enables 'Powered by Garuda' framework for connectivity and automation.

sbx-corp.com
+2 more records
Core offering1 text field

SBX Corporation develops and customizes AI software platforms — Garuda Platform (connectivity and automation), Taxila Platform (NLP/NLU text mining) and Gandhara AI Framework (ensemble machine learning) — to support scientific discovery in drug discovery, toxicology, clinical research, healthcare and cosmetics R&D. The company also delivers bespoke AI solutions through co-development partnerships, such as the AIM POLAR R&D platform built with POLA Chemical Industries and AI mutagenicity prediction systems built with Eisai.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Mutagenicity prediction AUC of 0.93 on Hansen benchmark dataset
+1 more record
Product overview1 text field

SBX Corporation offers a platform-plus-modules architecture built around three core platforms: Garuda Platform for connectivity and automation, Taxila Platform for text-mining and analytics, and Gandhara AI Framework for machine learning and intelligence. These platforms serve as basic infrastructure for scientific discovery in drug discovery, clinical trials, and healthcare. The company also provides custom solutions including AIM POLAR (cosmetics R&D platform) and AI for sensory design, both developed with partner POLA Chemical Industries.

Product and service6 records
1Garuda Platform
CategoryAI platform — connectivity and automation
Description

Open, community-driven platform that provides a framework to connect, discover and navigate different applications, databases and services in biology and medicine, enabling connectivity and automation of diverse data, devices and analytics at scale. Built for life sciences, biomedical and healthcare R&D teams.

2Taxila Platform
CategoryAI platform — text mining and knowledge aggregation
Description

End-to-end analysis and intelligence platform combining NLP/NLU algorithms to analyze text in context, providing automatic context-aware aggregation and search of relevant scientific information via an AI-powered mining and analytics engine. Targeted at researchers and knowledge workers in drug discovery, life sciences and healthcare.

3Gandhara AI Framework
CategoryAI framework — ensemble machine learning
Description

Machine learning and intelligence framework providing an ensemble learning approach that integrates many ML and deep learning algorithms for big-data analytics focused on biomedicine and healthcare, delivering actionable and explainable insights. Used by SBX's research team and partners for predictive modeling tasks including mutagenicity prediction.

4AIM POLAR
CategoryCustom AI R&D platform — cosmetics formulation
Description

Revolutionary R&D platform for cosmetics jointly built with POLA Chemical Industries. Custom AI engines translate historical formulation data into precise predictions for product texture, safety and stability, with an intuitive touchpoint for researchers. For enterprise cosmetics R&D teams.

5AI for sensory design (触感づくりAI)
CategoryCustom AI solution — cosmetics formulation
Description

AI tool that predicts sensory scores from cosmetic formulation information, enabling efficient and accurate in-silico prototyping for environmentally-friendly cosmetics development. For enterprise cosmetics R&D and product development teams.

6AI Mutagenicity Prediction System
CategoryCustom AI solution — predictive toxicology
Description

AI-based mutagenicity prediction system using machine-learning models trained on molecular structures, molecular properties and structural alerts to predict compound mutagenicity with high accuracy (AUC of 0.93 on the Hansen benchmark dataset). Developed with Eisai Co., Ltd. for use in drug discovery and toxicology risk assessment by pharmaceutical R&D teams.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1POLA Chemical Industries Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

SBX and POLA Chemical Industries jointly built the AIM POLAR R&D platform, a revolutionary system for cosmetics research. SBX was responsible for complete technical development, from the AI engine to user interface. POLA Chemical Industries provided deep industry knowledge and historical formulation data. This represents a true co-creation effort where SBX built custom AI engines to translate POLA's data into predictions for product texture, safety, and stability.

sbx-corp.com
2Eisai Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-08
Description

Long-standing collaboration on AI mutagenicity prediction systems. Presented jointly at JSOT 2021 on 'Development of AI mutagenicity prediction system incorporating the knowledge of expert review'. Multiple co-authored publications including work on optimizing machine-learning models for mutagenicity prediction published in Mutagenesis journal.

sbx-corp.com
3COVID-19 Disease Map Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-21
Description

Dr. Hiroaki Kitano of SBX participated in the global COVID-19 Disease Map initiative, co-authoring the paper 'COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms' in Scientific Data (Nature).

sbx-corp.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SBI is a non-profit private research institution established in 2000, affiliated with SBX Corporation. Focuses on promoting systems biology research and its application to medicine and global sustainability. Rapid translation of basic research to practical outcomes for business and clinical applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Provides solutions to complex socio-industrial problems using AI/ML, IoT/sensor networks, and model-based simulation techniques. Part of the SBX Group ecosystem, solving problems pertinent to industrial and societal issues.

6SBX BioSciences, Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Canadian subsidiary established in 2020 in Vancouver. Provides professional services and end-to-end research solution building towards predictive biology, integrating AI and computational systems biology, and platform-empowered research by partnering with group entities.

sbx-corp.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Engineering partner listed on SBX website, providing software development and technical expertise.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Engineering partner listed on SBX website, providing technology consulting services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

IMDA hosted the Agentic AI in Healthcare seminar in Singapore on August 29, 2025, where SBX was a key presenter sharing insights from real-world experiences. Government agency promoting digital transformation in Singapore.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SBX Corporation

AI Drug Discovery Platformssbx-corp.com

SBX Corporation is a private Tokyo-based AI company that builds proprietary platforms (Garuda, Taxila, Gandhara) for AI-driven scientific discovery in biomedicine and drug discovery, serving enterprise pharmaceutical and cosmetics clients through co-development partnerships and consulting.

What SBX Corporation does

SBX Corporation is a private Tokyo-based AI company founded on April 5, 2011, focused on building infrastructure for AI-driven scientific discovery in biomedicine and drug discovery. Its core technology stack consists of three proprietary platforms: Garuda Platform, which provides an open, community-driven framework for connecting and automating diverse biological data, devices, and analytics; Taxila Platform, an NLP/NLU-based text mining and intelligence engine for context-aware scientific literature analysis; and Gandhara AI Framework, an ensemble-learning system that integrates multiple machine learning and deep learning algorithms to deliver actionable and explainable insights in biomedicine. The company applies these platforms to drug discovery, clinical trials, healthcare, and adjacent domains.

SBX serves enterprise customers primarily through B2B co-development partnerships, joint research, and consulting engagements rather than standardized product sales. Named enterprise customers include POLA Chemical Industries (joint AIM POLAR R&D platform for cosmetics formulation) and Eisai (long-running AI mutagenicity prediction research). Revenue streams derive from R&D collaboration, custom software platform development and maintenance, and consulting services. The company operates through a group structure that includes the parent SBX Corporation (Tokyo), SBX Technologies Corporation (AI/ML, IoT, and model-based simulation), SBX BioSciences, Inc. (Vancouver, Canada, established 2020), and the affiliated non-profit Systems Biology Institute.

The company is led by President Hiroaki Kitano, Ph.D., a recognized pioneer in systems biology, supported by a team of Ph.D.-level scientists and engineers. With 11-50 employees and registered capital of JPY 5,000,000, SBX is a small, research-oriented firm that leverages academic publications, open-standards community participation (Garuda Alliance, SBML, SBGN, OpenTox), and conference engagement as core credibility and demand-generation channels, alongside direct enterprise relationships.

SBX Corporation firmographics

Firmographics
Name
SBX Corporation
Legal name
SBX Corporation
Website
https://sbx-corp.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
SBX Corporation is a private Tokyo-based AI company that builds proprietary platforms (Garuda, Taxila, Gandhara) for AI-driven scientific discovery in biomedicine and drug discovery, serving enterprise pharmaceutical and cosmetics clients through co-development partnerships and consulting.
Ownership category
akta.pro rank

SBX Corporation industry classification

Industry
Product category
AI Drug Discovery Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services

Keywords

  • AI drug discovery
  • Biomedical AI platforms
  • Systems biology software
  • Predictive toxicology AI
  • Cosmetics R&D AI

Where SBX Corporation is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

SBX Corporation business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. R&D Collaboration and Joint Development: SBX engages in co-development partnerships with pharmaceutical and cosmetics companies, building custom AI platforms and solutions. Revenue derived from collaborative development projects, such as the AIM POLAR platform with POLA Chemical Industries and mutagenicity prediction systems with Eisai.
  2. Software Platform Development and Customization: Development, customization and maintenance of software platforms for drug discovery and life science research. Provides platforms (Garuda, Taxila, Gandhara) that can be customized for specific client needs.
  3. Consulting Services: Information provision and consulting on life science, drug discovery, and medical fields. R&D consulting and joint development services in drug discovery and personal genome areas.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

SBX Corporation product offering

Product offering

Core offering

SBX Corporation develops and customizes AI software platforms — Garuda Platform (connectivity and automation), Taxila Platform (NLP/NLU text mining) and Gandhara AI Framework (ensemble machine learning) — to support scientific discovery in drug discovery, toxicology, clinical research, healthcare and cosmetics R&D. The company also delivers bespoke AI solutions through co-development partnerships, such as the AIM POLAR R&D platform built with POLA Chemical Industries and AI mutagenicity prediction systems built with Eisai.

Product overview

SBX Corporation offers a platform-plus-modules architecture built around three core platforms: Garuda Platform for connectivity and automation, Taxila Platform for text-mining and analytics, and Gandhara AI Framework for machine learning and intelligence. These platforms serve as basic infrastructure for scientific discovery in drug discovery, clinical trials, and healthcare. The company also provides custom solutions including AIM POLAR (cosmetics R&D platform) and AI for sensory design, both developed with partner POLA Chemical Industries.

Differentiator

Problem solved

Functional benefit

Brands

  • Garuda Platform: Open, community-driven platform providing framework to connect, discover and navigate through different applications, databases and services in biology and medicine. Also enables 'Powered by Garuda' framework for connectivity and automation.
  • Taxila Platform
  • Gandhara AI Framework

Products and services

  • Garuda Platform Open, community-driven platform that provides a framework to connect, discover and navigate different applications, databases and services in biology and medicine, enabling connectivity and automation of diverse data, devices and analytics at scale. Built for life sciences, biomedical and healthcare R&D teams.
  • Taxila Platform End-to-end analysis and intelligence platform combining NLP/NLU algorithms to analyze text in context, providing automatic context-aware aggregation and search of relevant scientific information via an AI-powered mining and analytics engine. Targeted at researchers and knowledge workers in drug discovery, life sciences and healthcare.
  • Gandhara AI Framework Machine learning and intelligence framework providing an ensemble learning approach that integrates many ML and deep learning algorithms for big-data analytics focused on biomedicine and healthcare, delivering actionable and explainable insights. Used by SBX's research team and partners for predictive modeling tasks including mutagenicity prediction.
  • AIM POLAR Revolutionary R&D platform for cosmetics jointly built with POLA Chemical Industries. Custom AI engines translate historical formulation data into precise predictions for product texture, safety and stability, with an intuitive touchpoint for researchers. For enterprise cosmetics R&D teams.
  • AI for sensory design (触感づくりAI) AI tool that predicts sensory scores from cosmetic formulation information, enabling efficient and accurate in-silico prototyping for environmentally-friendly cosmetics development. For enterprise cosmetics R&D and product development teams.
  • AI Mutagenicity Prediction System AI-based mutagenicity prediction system using machine-learning models trained on molecular structures, molecular properties and structural alerts to predict compound mutagenicity with high accuracy (AUC of 0.93 on the Hansen benchmark dataset). Developed with Eisai Co., Ltd. for use in drug discovery and toxicology risk assessment by pharmaceutical R&D teams.

Quantifiable outcome

  • Mutagenicity prediction AUC of 0.93 on Hansen benchmark dataset
  • +1 more outcomes

Companies that use SBX Corporation

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

SBX Corporation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

SBX Corporation partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • POLA Chemical Industries Inc.coreStrategic or Co-development Partner · 4 September 2025SBX and POLA Chemical Industries jointly built the AIM POLAR R&D platform, a revolutionary system for cosmetics research. SBX was responsible for complete technical development, from the AI engine to user interface. POLA Chemical Industries provided deep industry knowledge and historical formulation data. This represents a true co-creation effort where SBX built custom AI engines to translate POLA's data into predictions for product texture, safety, and stability.
  • Eisai Co., Ltd.coreStrategic or Co-development Partner · 8 July 2021Long-standing collaboration on AI mutagenicity prediction systems. Presented jointly at JSOT 2021 on 'Development of AI mutagenicity prediction system incorporating the knowledge of expert review'. Multiple co-authored publications including work on optimizing machine-learning models for mutagenicity prediction published in Mutagenesis journal.
  • COVID-19 Disease Map ConsortiumcoreStrategic or Co-development Partner · 21 April 2020Dr. Hiroaki Kitano of SBX participated in the global COVID-19 Disease Map initiative, co-authoring the paper 'COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms' in Scientific Data (Nature).
  • The Systems Biology Institute (SBI)coreStrategic or Co-development PartnerSBI is a non-profit private research institution established in 2000, affiliated with SBX Corporation. Focuses on promoting systems biology research and its application to medicine and global sustainability. Rapid translation of basic research to practical outcomes for business and clinical applications.
  • SBX Technologies CorporationcoreStrategic or Co-development PartnerProvides solutions to complex socio-industrial problems using AI/ML, IoT/sensor networks, and model-based simulation techniques. Part of the SBX Group ecosystem, solving problems pertinent to industrial and societal issues.
  • SBX BioSciences, Inc.coreStrategic or Co-development PartnerCanadian subsidiary established in 2020 in Vancouver. Provides professional services and end-to-end research solution building towards predictive biology, integrating AI and computational systems biology, and platform-empowered research by partnering with group entities.
  • alumnus Software LtdminorImplementation/ SI/ Consulting PartnerEngineering partner listed on SBX website, providing software development and technical expertise.
  • vikasietumminorImplementation/ SI/ Consulting PartnerEngineering partner listed on SBX website, providing technology consulting services.
  • Infocomm Media Development Authority (IMDA) SingaporeminorStrategic or Co-development PartnerIMDA hosted the Agentic AI in Healthcare seminar in Singapore on August 29, 2025, where SBX was a key presenter sharing insights from real-world experiences. Government agency promoting digital transformation in Singapore.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

SBX Corporation competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SBX Corporation social profiles

Digital presence

SBX Corporation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SBX Corporation leadership team

Management profile

Number of profiles

Profiles17 records

SBX Corporation subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

SBX Corporation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SBX Corporation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SBX Corporation

What does SBX Corporation do?

SBX Corporation develops and customizes AI software platforms — Garuda Platform (connectivity and automation), Taxila Platform (NLP/NLU text mining) and Gandhara AI Framework (ensemble machine learning) — to support scientific discovery in drug discovery, toxicology, clinical research, healthcare and cosmetics R&D. The company also delivers bespoke AI solutions through co-development partnerships, such as the AIM POLAR R&D platform built with POLA Chemical Industries and AI mutagenicity prediction systems built with Eisai.

Is SBX Corporation a public or private company?

SBX Corporation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SBX Corporation founded?

SBX Corporation was founded in 2011. It employs 11 to 50 people.

Where is SBX Corporation based?

SBX Corporation is headquartered in Tokyo, Japan, in the Asia region.

How does SBX Corporation make money?

Three revenue lines are on record. R&D Collaboration and Joint Development is the primary driver. The others are software Platform Development and Customization and consulting Services.

Does SBX Corporation have an API?

No public API is recorded for SBX Corporation.

What industry is SBX Corporation in?

SBX Corporation's product category is AI Drug Discovery Platforms. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAK, Pharmacovigilance & Drug Safety Software. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales